Vaxart, a San Francisco-based biotech company, has announced that the first volunteer in their Phase 1 trial of oral coronavirus vaccine, VXA-CoV2-1, has been given the vaccine. VXA-CoV2-1 is a recombinant adenoviral mucosal vaccine.
Pre-clinical data showed that the vaccine induces both a robust systemic immune response (humoral and cellular) and a strong mucosal immune response, specifically in the lungs.
The Phase 1 trial will enrol 48 healthy adult volunteers aged 18 to 54 years. Participants will receive the low or high dose of the VXA-CoV2-1 oral tablet at days 1 and 29. Safety, reactogenicity and immunogenicity assessments will be performed at set times during the trial.